A research team has discovered an enhanced CRISPR gene-editing system that could enable targeted delivery inside the human ...
Two-year disease-free survival from evaluable Phase 2 patients expected by the end of Q1 2028. Strasbourg, France, April 13, 2026, 8:00 a.m. CET - Transgene (Euronext Paris: TNG), a biotech company th ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results